PDSB
PDS Biotechnology Corp
NASDAQ · Healthcare · Biotechnology · US
$0.92
−18.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.14
From 52W high−42.72%
Volume8.41M
Market cap$66.42M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.14
From 52W high
−42.72%
Volume
8.41M
Market cap
$66.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
P/E (TTM)
—
RSI (14)
50.1
MomentumView details →
1D Return
−18.89%
YTD Return
+26.38%
SummaryUpdated Jun 1, 2026
PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Florham Park, New Jersey. The company focuses on developing multifunctional cancer immunotherapies using its proprietary Versamune platform technology. Since going public in 2015, PDS has advanced multiple product candidates through clinical trials, with its lead program targeting HPV-positive cancers currently in Phase 3 development. The company operates as a pure-play biotechnology firm with no current revenue, relying on clinical trial advancement and potential partnerships to drive value creation.
Similar companies
Latest newsMore news →
PDS Biotechnology Corp amended its $6,000,000 promissory note with YA II PN, Ltd., modifying payment and cure-period terms, including a mandatory deemed redemption of proceeds from non-ATM equity financings.45d agoPDS Biotechnology Corp terminated Stephan Toutain as Chief Operating Officer, effective August 21, 2026, with severance of twelve months' base salary and COBRA contributions.56d agoLars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corp, effective September 12, 2026, and Janetta Trochimiuk was appointed interim Principal Accounting Officer effective the same date.62d ago